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Transmembrane signaling by receptor tyrosine ki-
nases (RTKs) entails ligand-mediated dimerization
and structural rearrangement of the extracellular
domains. RTK activation also depends on the
specific orientation of the transmembrane domain
(TMD) helices, as suggested by pathogenic, consti-
tutively active RTK mutants. Such mutant TMDs
carry polar amino acids promoting stable transmem-
brane helix dimerization, which is essential for kinase
activation. We investigated the effect of polar amino
acids introduced into the TMD of vascular endothe-
lial growth factor receptor 2, regulating blood vessel
homeostasis. Two mutants showed constitutive
kinase activity, suggesting that precise TMD orienta-
tion is mandatory for kinase activation. Nuclear
magnetic resonance spectroscopy revealed that
TMD helices in activated constructs were rotated
by 180 relative to the interface of the wild-type con-
formation, confirming that ligand-mediated receptor
activation indeed results from transmembrane helix
rearrangement. A molecular dynamics simulation
confirmed the transmembrane helix arrangement
of wild-type and mutant TMDs revealed by nuclear
magnetic resonance spectroscopy.
INTRODUCTION
The human genome encodes 58 receptor tyrosine kinases
(RTKs) that regulate cellular activities such as growth, migration,
differentiation, and survival. RTKs exist either as preformed di-
mers or are dimerized upon ligand binding. In both cases, ligand
binding leads to conformational changes in the receptor extra-
cellular domain (ECD), as for instance shown for type I, III, IV,
and V RTKs (Schlessinger, 2003; Lemmon and Ferguson,Structure 22, 10772007). The structural changes in the ECD of receptor dimers
subsequently instigate transmembrane signaling by reorienting
the intracellular kinase domains.
We studied vascular endothelial growth factor receptors
(VEGFRs) that regulate blood and lymphatic vessel development
and homeostasis. Deregulated VEGFR signaling, resulting for
instance from overexpression of VEGF or VEGF receptors,
causes many pathologies (Koch et al., 2011), and mutation of
VEGFR-2 has been shown to be associated with juvenile heman-
gioma (Jinnin et al., 2008). In addition to extensive biochemical
evidence, structural analysis by single particle electron micro-
scopy (Ruch et al., 2007), small angle X-ray solution scattering
(Kisko et al., 2011), and X-ray crystallography (Leppa¨nen et al.,
2013; Brozzo et al., 2012; Leppa¨nen et al., 2010) showed that
ligand binding to VEGFR-2 promotes receptor dimerization.
These studies also show that structural rearrangements in
membrane-proximal VEGFR-2 ECD subdomains allosterically
regulate receptor activation (Hyde et al., 2012). High-resolution
structural information is also available for other ligand-RTK
complexes (Yuzawa et al., 2007; Stauber et al., 2000; Pellegrini
et al., 2000; Plotnikov et al., 1999; Liu et al., 2007; Barton
et al., 2006; Ogiso et al., 2002), and X-ray crystallography of
soluble kinase domain constructs revealed essential details
regarding the mechanism of RTK activation (Zhang et al., 2006;
Walter et al., 2007; Schubert et al., 2007). The kinase domains
of epidermal growth factor receptor (EGFR) and fibroblast
growth factor receptor (FGFR), for instance, have been shown
to form asymmetric dimers stabilized by interactions between
the juxtamembrane domain and the upper and lower lobes of
the kinase (Endres et al., 2013; Zhang et al., 2006; Bae et al.,
2010; Jura et al., 2009). These asymmetric dimers represent
the active state of these receptor kinases and have also been
confirmed for the full-length EGFR (Mi et al., 2011) and FGFR
(Opatowsky et al., 2014) by single particle electron microscopy.
The importance of dimerization in RTK activation is, therefore,
well documented, and aberrant signaling because of mutations
that lead to ligand-independent dimer formation are the cause
of many diseases. For example, ligand-independent dimeriza-
tion of mutant Neu receptors, an EGFR homolog, promotes–1089, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1077
Figure 1. Kinase Activities of Single Glutamic Acid TMDMutants of DECD-VEGFR-2 and Double Glutamic Acid TMDMutants of Full-Length
VEGFR-2 Constructs Determined by Analysis of Y1175 Phosphorylation on Western Blots
(A and B) Graphs show the quantification of three independent experiments with SD. The y axis represents relative activity. Figure S1 shows a summary of the
constructs used in this analysis.
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VEGFR-2 Transmembrane Domain Structuretumorigenesis (Bargmann and Weinberg, 1988; Smith et al.,
1996). Such Neu mutants carried a valine-to-glutamic acid
substitution in the transmembrane domain (TMD) that led to
ligand-independent receptor activation (Smith et al., 1996; Gul-
lick et al., 1992). Similarly, mutation of the TMD of FGFR3 causes
developmental disorders such as bone malformation or onco-
genic transformation (Kelleher et al., 2013; Webster and Donog-
hue, 1996). Based on these results, Bell et al. (2000) engineered
constitutively dimerized Neu and platelet-derived growth factor
receptor (PDGFR) constructs by replacing the TMDwith a hydro-
phobic helix comprising 25 valine residues interrupted by two
polar amino acids, such as glutamic acid, spaced seven amino
acids apart and, therefore, located on the same face of the helix
(Bell et al., 2000). These mutations gave rise to highly stable
dimers that were either active or inactive, depending on where
the polar residues were located in the TMD. We applied this
concept to VEGFR-2 and found that only one distinct confor-
mation rendered the receptor constitutively active, showing
that receptor dimerization is necessary, but not sufficient, for
VEGFR-2 activation (Dosch and Ballmer-Hofer, 2010).
Here we applied scanning mutagenesis to the WT TMD and
correlated the activity of constructs carrying glutamic acid resi-
dues in specific positions with their structure determined by
nuclear magnetic resonance (NMR) spectroscopy. Molecular
dynamics (MD) simulations further support the structural and
dynamic interpretation of the NMR data. Our data show that
introducing two polar amino acids in distinct positions of the
TMD reorients transmembrane helices and leads to stable dimer
formation. Therefore, we infer that the transition between the
inactive and the active dimeric state of VEGFR-2 implicates
alternative dimeric TMD conformations.1078 Structure 22, 1077–1089, August 5, 2014 ª2014 Elsevier Ltd AlRESULTS
Construction and Analysis of Constitutively Dimerized
VEGFR-2 TMD Variants
To investigate the role of the TMD in VEGFR-2 signaling, we
generated constitutively dimerized, ECD-truncated and full-
length receptor constructs. These constructs carried transmem-
brane helices with either one or two residues replaced by
glutamic acid (for a summary scheme of all constructs, see Fig-
ures S1A and S1B available online). The ECD-deleted construct
carrying glutamic acid in position 769 (V769E) exhibited the high-
est activity (Figure 1A, top panels), whereas the mutants I767E
and L768E had a lower, but still increased activity compared
with the WT TMD construct. The ECD-deleted WT TMD
construct showed only 20%–30% of the activity of the activating
mutants but was clearly more active than the full-length receptor
in the absence of ligand, reaching about 50%of the activity of the
ligand-stimulated, full-length receptor (Figure S2A). This shows,
similar to other RTKs, that receptor dimerization and, thus,
kinase activation is negatively regulated by the ECD (Dosch
and Ballmer-Hofer, 2010).
In the full-length VEGFR-2, the V769E mutation was not acti-
vating, presumably because of steric constraints by the recep-
tor ECD that prevent the proper alignment of the two helices in
the membrane. As a matter of fact, none of the single mutant
TMD constructs showed ligand-independent activity (Figure S3).
Therefore, we generated double mutant TMD constructs car-
rying two glutamic acid residues spaced seven amino acids
apart. In these constructs, the polar amino acids are predicted
to face the same side of the TMD, giving rise to highly stable di-
mers. Figure 1B shows that the G770E/F777E and T771E/F778El rights reserved
Figure 2. NMR Data and Secondary Struc-
ture of the Peptides VEGFR-2tm, VEGFR-
2tm769, and VEGFR-2tm770/777
(A–C) Sequential and medium-range character-
istic NOE-based distances (dXX(i1,i2) are shown as
horizontal lines. Line thickness is proportional to
the intensity of the corresponding peak in the
NOESY spectrum. Meaningless contacts, i.e.,
contacts that do not impose any restraints on the
structure, were removed by the built-in algorithm
in the CYANA software (Guentert, 2003). P_helix is
the a helix propensity predicted by the TALOS+
(Shen et al., 2009) software on the basis of NMR
chemical shifts.
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VEGFR-2 Transmembrane Domain Structuremutants had high constitutive receptor activity, which was not
increased further by ligand addition. To rule out improper intra-
cellular trafficking of such constructs and, thus, inaccessibility
to extracellular ligand, we compared the membrane localization
of WT and mutant TMD receptors by immunofluorescence mi-
croscopy in transfected COS-7 cells. To further demonstrate
membrane localization of these mutant receptors, the cells
were cotransfected with a plasmid encoding a fluorescent
membrane marker. We used an enhanced green fluorescent
protein (EGFP) fusion protein of the pleckstrin homology (PH)
domain of phospholipase d that binds to phosphatidylinositol
4,5-bisphosphate. VEGFR-2 was labeled prior to fixation with
an antibody recognizing the receptor ECD (Figure S2B). In
agreement with our work published earlier, confocal micro-
scopy clearly showed plasma membrane staining of both
the eGFP-PH membrane marker and VEGFR-2 (Dosch and
Ballmer-Hofer, 2010).
Taken together, our data show that replacement of a single
residue in the TMD by a polar amino acid in either of three posi-
tions is sufficient for activation of ECD-truncated VEGFR-2,
whereas mutation of two residues in either of two positions is
required for activation of full-length receptors.Structure 22, 1077–1089, August 5, 2014 ªNMR Analysis and 3D Structure of
WT and Mutant TMDs in DPC
Micelles
To analyze the effect of the identified
mutations on the structural and thermo-
dynamic properties of TMD helix-helix in-
teractions, we determined the structures
and measured the free energies of dimer-
ization for peptides representing WT
(VEGFR-2tm) and the activating mutants
VEGFR-2tm769 and VEGFR-2tm770/
777. TMD peptides were produced
in vitro and inserted into membrane-
mimetic dodecylphosphocholine (DPC)
micelles. NMR chemical shifts, nuclear
Overhauser effect (NOE) connectivities,
and NMR relaxation data revealed that
the WT peptide forms a long a helix be-
tween residues 761 and 794 (Figure 2).
VEGFR-2tm existed in two forms, with
population states depending on the
detergent-to-protein ratio (for details,see Supplemental Experimental Procedures). Dilution by deter-
gent revealed that these states represented monomers and
dimers, respectively. The monomer-dimer transition was very
slow, in the range of seconds, with the free energy of dimeriza-
tion equal to 2.1 ± 0.2 kilocalories (kcal)/mol (Figure 3A). The
reported free energies were obtained as described by Mineev
et al. (2014), using standard conditions corresponding to a
micelle concentration of 1M. The free energy of dimerization of
VEGFR-2tm was clearly lower than that observed for other
RTKs, such as ErbB3 (0.5 kcal/M), ErbB4 (1.5 kcal/M), and
FGFR3 (1.4 kcal/M).
For the WT VEGFR-2tm peptide, we detected nine inter-
monomeric contacts by heteronuclei-filtered NOE spectroscopy
(NOESY), which were used to calculate the 3D structure of
TMD dimers. A summary of NMR data and statistics of the calcu-
lated structures is given in Table 1. The WT structure represents
a symmetric, left-handed parallel dimer with an angle between
helical axes of 25 ± 1 (Figure 5A). The interface of dimerization
is long and encompasses almost the entire length of the
TMD segment. The interaction between a helices is accom-
plished via a heptad repeat-likemotif T761xxE764xxI767L768xxT771
A772xxA775xxF778W779xL781L782xxI785xxxV789. The association2014 Elsevier Ltd All rights reserved 1079
Figure 3. TROSY-HSQC Spectra of TMD
Peptides
(A–C) Signals arising from interhelical Nε-H in-
teractions between arginines 787 and 791 in
1H,15N-TROSY-HSQC spectra of the peptides
VEGFR-2tm (A), VEGFR-2tm769 (B), and
VEGFR-2tm770/777 (C). Cross-peaks originating
from different oligomeric states are assigned: M
(monomer), D (dimer) and T (trimer). All spectra
were acquired at lipid/protein ratios of 300:1 at 318
K and pH 4.5 on a Bruker AVANCE III 800-MHz
spectrometer.
(D) NMR-derived correlation time for the rotational
diffusion measured from cross-correlated relaxa-
tion rates of N-H groups of VEGFR-2tm769 for
three oligomeric states: monomer (yellow bars),
dimer (red bars), and trimer (blue bars).
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VEGFR-2 Transmembrane Domain Structureof the VEGFR-2tm peptide is stabilized by stacking of the aro-
matic side chains of F778 and W779 and by van der Waals con-
tacts between bulky side chains of hydrophobic residues. The
observed VEGFR-2tm dimer conformation is similar to previ-
ously determined structures of dimeric TMDs of EphA2
(Bocharov et al., 2010), ErbB3 (Mineev et al., 2011), and
FGFR3 (Bocharov et al., 2013).
We next studied the effect of the V769E substitution on the
VEGFR-2 TMD structure. The VEGFR-2tm769 peptide was
inserted into DPC micelles at pH 4.5. Under these conditions,
the side chains of E764 and E769 were protonated (Figure S5).
The NMR spectra of VEGFR-2tm769 were very similar to WT
VEGFR-2tm, displaying multiple contacts between methyl
groups in isoleucine, valine, and leucine residues to residual
protons of the DPC methyl groups in 13C-filtered NOESY (Fig-
ure 2). This shows that the peptide is in a ‘‘transmembrane’’
and not in a ‘‘surface-bound’’ orientation. The side chain of the
transmembrane E769 was protonated under both experimental
(pH 4.5) and physiological (pH 7.0) conditions (Figure S5).
The secondary chemical shifts show that the a helix of
VEGFR-2tm769 is present in the same section of the peptide
as in theWT. Unlike theWT, the single mutant TMD formed three
oligomeric states, characterized by different correlation times for
rotational diffusion (Figures 4A and 4B; Figures S4A and S4B).
The samples were gradually diluted to determine peptide oligo-
merization and to measure the effect of the valine-to-glutamic
acid substitution on oligomerization propensity. Three models
for the oligomerization equilibrium were tested: monomer-
dimer1-dimer2, monomer-dimer-trimer, and monomer-dimer-
tetramer. The trimerization model best fit the data obtained
(Figures 3B and 3D; Figure S4B) with a free energy of the dimer
(DGdim) of 2.4 ± 0.2 kcal/mol and a free energy of the trimer
(DGtrim) of 2.9 ± 0.2 kcal/mol. The change in the free energy
of dimerization caused by the V769E mutation was insignificant,
accounting for only 0.3 kcal/mol, which is within the experimental
error. The population of the monomer, dimer, and trimer states
depended on the peptide-to-detergent ratio. We were not able
to calculate the dimer structure based on NOEs because the1080 Structure 22, 1077–1089, August 5, 2014 ª2014 Elsevier Ltd All rights reservedpopulation of the dimeric state was low
and NMR spectra were highly overlap-
ped. The trimeric state was very stable,and, even at a 200:1 DPC:protein ratio, almost 50% of the pep-
tide was present as trimers, precluding direct measurement of
the dimer structure.
The conformation of the VEGFR-2tm769 dimer peptide was
next studied by covariance analysis of N-H chemical shift
changes upon dimerization of WT and mutant TMDs. We plotted
the cosine of angle between vectors describing the shift of the
signal from the backbone N-H group in the 1H,15N transverse
relaxation optimized spectroscopy-heteronuclear single quan-
tum coherence (TROSY-HSQC) spectrum (Figure S6), resulting
from the dimerization ofWT ormutant peptides, versus the ratios
of their modules. To balance the contributions from changes
in proton and nitrogen shifts, chemical shift changes were
measured in hertz. Surprisingly, the vast majority of residues in
the hydrophobic helix showed a good correlation for the alter-
ation of amide proton and nitrogen chemical shifts during dimer-
ization, and the signals moved in similar directions and by similar
distances in NMR spectra upon dimerization of the WT and the
V769E mutant, showing that dimer structures are very similar.
The effect of the amino acid substitution on the structure of
VEGFR-2tm769 was further studied in TMD trimers. A concen-
trated sample (90% trimer) at a detergent-to-protein ratio of
60 was prepared, and an X-filtered NOESY spectrum was
recorded. The quality of this spectrum was poor because of
line broadening, which allowed the detection of only seven
interhelical contacts. A single set of NMR signals corresponded
to the trimeric state, and, therefore, this structure was treated
as a symmetric structure where seven interhelical contacts
were symmetrized to obtain 21 upper distance restraints, which
were used for structure calculation. The resulting structural
model is shown in Figure 5B. The trimer interface was compact
and located close to the N terminus of the hydrophobic
helix. The following residues were involved in helix-helix interac-
tions: T761xxE764I765xxL768E769xxA772V773xxM776F777xW779L780.
Trimer formation may be additionally supported by stacking of
aromatic side chains and by hydrogen bonds formed by the
side chains of E769. However, the quality of the obtained struc-
ture was too low to determine hydrogen bonding partners for
Table 1. StructuralStatistics for theEnsembleof the10BestNMR
Structuresof theVEGFR-2tmandVEGFR-2tm770/777Dimersand
the VEGFR-2tm769 Trimer in DPC Micelles at 318 K and pH 4.5
NMR Distance and Dihedral Restraints
TM domain WT 769E 770E/777E
Total unambiguous
NOE restraints
418 606 496
Intraresidue 98 150 194
Interresidue 302 435 302
Sequential (ji–jj = 1) 138 150 116
Medium-range (1 < ji–jj% 4) 164a 285 186
Long-range (ji–jj > 4) 0 0 0
Intermonomeric 18 21 28
Hydrogen bond restraints
(upper/lower)
162/162 243/243 162/162
Total torsion angle
restraints
136 204 138
Backbone 4 62 93 62
Backbone c 62 93 62
Side chain c1 12 18 14
Side chain c2 0 0
Structure Calculation Statistics
CYANA target function (A˚2) 1.2 ± 0.2 0.5 ± 0.1 4.6 ± 0.2
Restraint violations
Distance (>0.2 A˚) 2 3 8
Distance (>0.3 A˚) 0 0 0
Dihedral (>5)) 0 0 1
Average pairwise rmsd (A˚)
a-helical region
(761–794)2/(761–794)3
Backbone atoms 0.24 ± 0.08 1.5 ± 0.5 0.48 ± 0.23
All heavy atoms 0.74 ± 0.12 2.0 ± 0.4 0.87 ± 0.20
Ramachandran analysis
% of residues in most
favored regions
100.0 87.9 97.1
% of residues in additional
allowed regions
0 12.1 2.9
% of residues in generally
allowed regions
0 0 0
% of residues in disallowed
regions
0 0 0
Helix-Helix Packing
Contact surface area per
monomer in pair of
interacting helices (A˚2)
613 ± 20 340 ± 10 847 ± 20
Angle q between the helix
axes (degrees)
25 ± 1 50 ± 5 55 ± 5,
25 ± 5a
(18 ± 5)
Distance between the
C termini (A˚)
15.6 ± 0.6 30.7 ± 4.3 9.6 ± 0.7
aThe angle between helical axes was calculated separately for N-terminal
residues (761–769) and C-terminal residues (778–791) of VEGFR-
2tm770/777 because of the bending of the TMD a helix. The angle calcu-
lated for the whole TMD helices is given in parentheses.
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Structure 22, 1077E769. The overall fold allows this residue to contact the carbonyl
group of L768 and the amide group of A772. Geometric param-
eters of the asymmetric dimer in the trimers were similar to the
previously described structures of dimeric TMDs of ErbB2
(Bocharov et al., 2008), ErbB1/ErbB2 (Mineev et al., 2010), and
ErbB4 (Bocharov et al., 2012). The angle between the axis of
the helices was 50 ± 5, and the carboxyl termini were sepa-
rated by 20 A˚ in active dimers of these kinases based on 3D
structures of the extracellular and kinase domains (Jura et al.,
2011; Bocharov et al., 2008). Introduction of E769 into the
VEGFR-2 TMD does, therefore, not substantially enhance the
propensity for dimerization, but it creates an additional surface
for helix-helix interactions. We suppose that the observed trimer
conformation of this mutant only exists in the VEGFR-2tm769
peptide studied here and does not exist in larger dimeric protein
constructs because of steric interference of the ECDs. However,
the helix-helix dimer interface observed in VEGFR-2tm769
peptide trimers may reflect the actual conformation of the TMD
in the ECD-truncated V769E VEGFR-2 construct.
We next studied the structure of the VEGFR-2tm770/777 pep-
tide carrying two glutamic acid mutations that result in activation
of the full-length receptor (Figure 1B). Similar to the WT, two sets
of signals were found in the NMR spectra, indicative of two
distinct oligomeric states. The presence of the two highly polar
glutamic acid residues did not disturb the transmembrane orien-
tation of the peptide (Figure 2), as shown by the number of NOE
contacts between themethyl groups of the protein and themeth-
ylene groups of the lipid detergent phase (Figure S7). The
observed chemical shifts confirm that residues 761–794 form
an a helix (Figure 2) with both transmembrane glutamic acid
side chains protonated at pH 4.5 and 7.0 (Figure S5). Detergent
titration unambiguously revealed two conformational states: one
dimeric and the other monomeric, with a free energy of dimeriza-
tion of 3.2 ± 0.2 kcal/mol, which is substantially lower than the
free energy observed for WT VEGFR-2tm dimerization (Fig-
ure 3C). Thus, we conclude that VEGFR-2tm770/777 shows a
significantly higher dimerization propensity than the WT. Unlike
VEGFR-2tm and VEGFR-2tm769, where the dimeric state was
relatively rigid, as documented by the narrow signals in the
NMR spectra, the spectra of the VEGFR-2tm770/777 dimer
contained a number of very broad resonances from both back-
bone and methyl side chain nuclei (Figure S4C). In particular, a
large section of the backbone in the center of the a helix (amino
acids 768–779) was characterized by very broad signals in
1H,15N-TROSY-HSQC, whereas several signals from methyl
groups in the N-terminal half of the TMDwere weak (Figure S4C),
suggesting that the backbone of the VEGFR-2tm770/777 dimers
perform motions at the microsecond to millisecond time scale,
such as twisting, stretching, and bending, that are accompanied
by variations in the helix-helix interface.
Analysis of the 13C-filtered-NOESY NMR spectra of VEGFR-
2tm770/777 showed 14 intermolecular contacts, which we
used to calculate the structure of TMD dimers. Not all intermo-
lecular distance restraints could be satisfied simultaneously in
a single NMR structure, as reflected by the relatively high
CYANA target function and the bending of the TMD a helix.
Therefore, the obtained structure is an average between various
conformations of a symmetric (in the NMR time scale) parallel
dimer of two a helices (Figure 5C). TMD helices are bent between–1089, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1081
Figure 4. Oligomerization Constants of VEGFR-2 TMD Peptides
(A–F) Apparent free energies of oligomerization were calculated from intensities of signals in 1H,15N-TROSY-HSQC according to different models of TMD
oligomerization for VEGFR-2tm (A), VEGFR-2tm769 (B, dimerization; D, trimerization; E, two dimers; F, tetramerization), and VEGFR-2tm770/777 (C, dimerization)
were plotted versus the logarithm of concentration of emptymicelles. Red rectangles show data for samples after 2-fold dilution with water. For ‘‘true’’ models, all
points show linear dependence of the form y = ax+b, where a is gRT (see Supplemental Experimental Procedures) and b is the standard free energy (DG0). The
equations describing these dependences are shown in the plots. Standard conditions are 1M of empty DPC micelles at 318 K.
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VEGFR-2 Transmembrane Domain Structureresidues 769–778, in agreement with line broadening of the
backbone resonances (Figure 5D). The angle between the
straight amino- and carboxy-terminal sections of the a helices
is 30, and the angle between the axes of the TMDs is,
therefore, not well defined. The dimer interface involves the
following residues: K760xxL763xxI766IxV769ExxV773IxM776ExxL780
LxxI784IxxT788. Both glutamic acid residues are on the helix-helix
interface and form intermolecular hydrogen bonds with the
backbone of the opposing helix. However, the quality of the
NMR spectra is insufficient to determine the precise partner
amino acids. The helix-helix interface of the activating VEGFR-
2tm770/777 peptide is on the opposite side of the interface of
the WT TMD, in agreement with the observed chemical shifts
of the methyl groups. In particular, the d-methyl side chains of
L763 in the mutant differ from those of VEGFR-2tm, which
cannot be explained by the changes in the intramolecular envi-
ronment resulting from the introduction of glutamic acid in posi-
tions 770 and 777 (Figures S4A and S4C). Moreover, the free
energy of dimerization of VEGFR-2tm770/777 is insensitive to
the protonation state of E764, consistent with the fact that this
residue is not part of the dimerization interface (Figures 5C and
5D). This clearly distinguishes the activating VEGFR-2tm770/
777 from WT VEGFR-2tm and VEGFR-2tm769.
Taken together, three major aspects distinguish the VEGFR-
2tm770/777 dimer from the WT. Dimerization propensity is
enhanced by 1 kcal/mol; dimerization occurs via a completely
different interface lying on the opposite face of the helix; and the1082 Structure 22, 1077–1089, August 5, 2014 ª2014 Elsevier Ltd Alstructure of this dimer is flexible, which means that TMD helices
can bend and perform motions at a microsecond to millisecond
time scale.
MD Simulations of WT and Mutant TMD Dimers
Analysis of the trajectories for the WT TMDs shows that this sys-
tem is remarkably stable (Figure 6, black trace), maintaining the
interhelical aromatic and hydrophobic packing observed in the
NMR structure with only minor fluctuations of the side chains.
Interestingly, this is not the case in the simulation of the consti-
tutively active G770E/F777E mutant, where the TMDs rapidly
undergo significant structural changes from their starting con-
formation (Figure 6, red trace). Specifically, we observe that
residues 770 and 777 mutated to glutamic acid engage in an
interhelical ‘‘glutamic acid zipper’’ that stabilizes sliding of the
TMDs by 5 A˚ (Figure 7; Movie S1). This behavior agrees with
the NMR data showing that the structure of this mutant is
flexible, with motions promoting changes in the dimerization
interface.
We next asked whether these structural rearrangements are
also possible in the WT receptor by running an MD simulation
of a model of the WT TMD built on the NMR structure of the
G770E/F777E mutant. The trajectories show that this system is
relatively unstable and undergoes large structural rearrange-
ments, even at relatively short time scales (Figure 6, orange
trace). A more detailed analysis shows a rapid rearrangement
in the aromatic dimerization interface because of a change inl rights reserved
Figure 5. Structure of VEGFR-2 TMD Peptides
(A–C) The ten best NMR structures (shown as ribbons) were superimposed using the backbone atoms. Side chains of residues on the dimerization interface are
shown as gray (A), yellow (B), and green (C) sticks. The intermonomeric contact surface area of VEGFR-2 TMDs is shown as the percentage of the total solvent-
accessible area in the graphs in the left margin.
(D) Bending of double glutamic acid mutated TMD helix along the axis.
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VEGFR-2 Transmembrane Domain Structureside chain conformation of F777, which is accompanied by a
small rotation and sliding of the TMDs that, together, optimize
the aromatic interactions. However, this seemingly minor
rearrangement brings the basic residues R787, K790, and
R791 in close proximity at the cytoplasmic side of the helices.
As a result, the C-terminal ends of the TMDs move 15 A˚ apart,
thereby minimizing the electrostatic repulsion between these
positively charged residues (Figure 8; Movie S2). These large
rearrangements are likely not biologically relevant for WT
VEGFR-2 activation and simply result from the lack of a stabiliz-
ing mechanism of the active arrangement in the WT sequence,
e.g., the glutamic acid zipper in the G770E/F777E mutant (Fig-
ure 7) or from VEGF-mediated interactions in the ECDs of the
full-length WT receptor.
In the absence of NMR data for the inactivating I774E/L781E
mutant, we tested the possible impact of these mutations using
the WT conformation as a template for MD simulation. We found
that E774 and E781 do not engage in interhelical interactions and
that the hydrophobic and aromatic dimerization interfaces were
maintained during simulation. Therefore, this system remains
remarkably stable (Figure 6, blue trace). We consider the highStructure 22, 1077stability of this conformation, which is similar to the WT, to be
the reason for the inactive phenotype of this mutant.
DISCUSSION
Transmembrane signaling by RTKs requires specific orientation
of the intracellular kinase domains in active receptor dimers.
Earlier studies showed that replacing small hydrophobic resi-
dues with polar amino acids in the TMD, as observed, for
instance, in naturally occurring FGFR mutants, causes severe
developmental pathologies, such as Crouzon syndrome, achon-
droplasia, or oncogenic transformation (Li et al., 2006; Webster
and Donoghue, 1996; Li et al., 1997). This results from a
decrease in the free energy of dimerization by approximately
1.3 kcal/mol (Chen et al., 2010b). Similar mutations observed
in Neu receptors led to oncogenic transformation (Bargmann
and Weinberg, 1988). Based on these observations, constitu-
tively active PDGFR-b, Neu (Bell et al., 2000), and VEGFR-2
(Dosch and Ballmer-Hofer, 2010) mutants were generated that
carry dimerization-promoting TMDs consisting of 23 valine and
2 glutamic acid residues. All mutants gave rise to constitutive–1089, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1083
Figure 6. Root-Mean-Square Deviation of the Ca Atoms from the
Initial Structure in the MD Simulations
The NMR structure of the WT TMDs (black trace) and the model of the I774E/
L781E mutant built on this structure (blue trace) stabilize rapidly in a confor-
mation very close to the starting structure. Thus, these arrangements of the
TMDs likely represent stable local minima. However, the NMR structure of
the G770E/F777E mutant (red trace) and the model of the WT sequence built
on this structure (orange trace) rapidly undergo significant conformational
changes that lead these systems to adopt different relative arrangements of
the TMDs.
Structure
VEGFR-2 Transmembrane Domain Structurereceptor dimers, yet only a small subset showed increased
ligand-independent activity, illustrating that dimerization is
necessary, but not sufficient, for activation. Here we further1084 Structure 22, 1077–1089, August 5, 2014 ª2014 Elsevier Ltd Alapplied scanning mutagenesis to the TMD of VEGFR-2 and
determined the activity of mutant constructs and the exact
spatial conformation of transmembrane helix dimers.
Kinase activity was increased in ECD-deleted VEGFR-2
compared with the full-length receptor, and this activity was
increased further upon mutation of either I767, L768, or V796
to glutamic acid. However, a single polar amino acid mutation
did not activate the full-length receptor, presumably because
the change in the free energy of dimerization was too small to
compensate for receptor repulsion by the ECD and/or negative
steric interference between the TMD and the ligand-bound
ECD. Taken together, this suggests that, in the absence of
ligand, the ECD impedes receptor activation, maintaining recep-
tors in an inactive conformation, as shown earlier for EGFR
(Ferguson et al., 2003) and FGFR (Chen et al., 2010b).
Therefore, we generated double glutamic acid TMD VEGFR-2
mutants. G770E/F777E and I771E/L778E displayed constitu-
tively high ligand-independent activity. In agreement with earlier
publications, this demonstrates that TMDs carrying two polar
amino acids show a high dimerization propensity and, when
the mutant residues are correctly positioned, activate RTKs
(Bell et al., 2000; Dosch and Ballmer-Hofer, 2010). A thermody-
namic analysis of ligand binding to the ECD of VEGFR-2 showed
that homotypic interactions in the membrane-proximal part
of the receptor ECD destabilize ligand-receptor dimers byFigure 7. Structural Rearrangements in
the G770E/F777E Mutant Observed in MD
Simulations
(A) NMR structure of the G770E/F777E mutant
TMD peptide (left) and final structure in the
MD simulation (right). Structural rearrangements
during the simulation result in the formation of a
glutamic acid zipper (hydrogen bonds are shown
as broken lines) and sliding of the TMDs relative to
each other.
(B) Sliding can be observed as a significant
conformational change early in the simulation
(e.g., in the root-mean-square deviation [rmsd]
profile, red trace) that can be quantified by
measuring the distances between E770 and E777
in opposite helices [green and orange lines in (A),
left, and traces in (B)]. See also Movie S1.
l rights reserved
Figure 8. Structural Rearrangements in theWTTMDObserved inMD
Simulations
The model on the left shows the active conformation of WT TMDs. This
structure has the same dimerization interface as the NMR structure of the
G770E/F777E double mutant (Figure 5C), with the exception of the contacts
mediated by residues 770 and 777. On the right, MD simulations show that
relocation of the interhelical aromatic-aromatic interactions mediated by
F777 and F778 in the WT TMD peptide results in a small helix sliding and
rotation that is further amplified into a large rearrangement of the helix
C-terminal domains. These regions move 15 A˚ apart in the course of the
simulation, to a final distance of 25 A˚. See also Movie S2. Thus, the absence
of the glutamic acid zipper in the WT TMDs (compare with Figure 7)
increases structural flexibility.
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VEGFR-2 Transmembrane Domain Structure1.01.7 kcal/mol (Brozzo et al., 2012). Because the V769E
mutant only insignificantly decreased the free energy of dimer-
ization, our data explain why a second polar residue is required
for constitutive dimer formation of VEGFR-2. This is in full agree-
ment with similar thermodynamic data published for FGFR3,
showing that two glutamic acid residues are required to stabilize
receptor dimers by the TMD (Chen et al., 2010a; Chen et al.,
2010b). Taken together, this shows that, in the absence of ligand,
the ECD acts as an energy barrier that prevents ligand-indepen-
dent VEGFR-2 activation. We propose that this proofreading
mechanism is biologically relevant to ensure tight control of
VEGF signaling.
Investigating the structural changes caused by glutamic acid
mutation of RTK TMDs, Bell et al. (2000) proposed a model in
which the rotational angle at which kinase subunits interact
with each other governs receptor activation. To identify the
TMD dimer structure required for kinase activation, we deter-
mined the structures of WT (VEGFR-2tm), single mutant
(VEGFR-2tm769), and double mutant (VEGFR-2tm770/777)
TMD peptides in DPC micelles applying NMR spectroscopy.
We found three distinct TMD conformations. The first conforma-
tion represents the dimeric structure of the inactive WT
VEGFR-2tm. VEGFR-2tm770/777, representing the activating
TMD, differed from the WT dimer conformation because of
rotation of the helices by 180. This suggests that the WT dimer
structure is either functionally meaningless or corresponds to
an inactive, predimerized state of VEGFR-2 as, for instance,
observed for EGFRs (Tao and Maruyama, 2008). This is sup-
ported by the high stability of the WT dimer (4.6 kcal/mol at
1M of detergent) compared with TMDs of other RTKs (Finger
et al., 2009). In addition, MD simulation of the I774E/L781E
TMD in the context of the WT dimer structure maintainedStructure 22, 1077the native hydrophobic and aromatic dimerization interface
observed in the NMR structure (Figure 6). In agreement with
the simulation of the active G770E/F777E mutant, E774 and
E781 did not form interhelical interactions, possibly because
the stable and bulky aromatic cluster formed by F777, F778,
and W779 localized in between the two mutant residues. The
aromatic residues sterically prevent helices from rotating and
sliding into an alternative conformation and, thus, trap the heli-
ces in the inactive WT conformation. As a consequence, I774E/
L781E substitutions render VEGFR-2 constitutively inactive
because of stabilization of the WT dimerization interface.
Therefore, we favor the idea that this WT dimeric structure rep-
resents the conformation of the receptor in a predimerized,
inactive state.
A second conformation was found for the VEGFR-2tm770/777
mutant and represents the active state of the full-length
VEGFR-2, as confirmed by our biochemical analysis. The posi-
tions of the glutamic acid residues in the activating (G770E/
F777E) and the inactivating (I774E/L781E) double mutants agree
well with our data published earlier using all valine TMDs of
VEGFR-2 (Dosch and Ballmer-Hofer, 2010). These conforma-
tions are stable enough to promote constitutive dimerization of
VEGFR-2, and G770E/F777E provides the free energy required
to compensate for steric repulsion by the receptor ECD. We
further studied the molecular details of the dimerization interface
of TMDs by MD simulation and modeled the conformations for
interhelical interactions. Such changes occur on a nanosecond
time scale (Henzler-Wildman and Kern, 2007), so they can be
captured in our simulations, which range between 120150 ns.
We found a number of interaction patterns and identified specific
residues that are key to understanding the molecular determi-
nants responsible for the phenotype of the G770E/F777E
mutant. Glutamic acid residues 770 and 777 engage in a gluta-
mic acid zipper that stabilizes the relative sliding of the TMDs
by 5 A˚. Such a sliding may be part of the motions suggested
by the NMR data, and it would also provide an additional source
of asymmetry probably required for receptor activation. We
also propose that phenylalanine 777 is a key regulator of the
dimerization interface because changes in side chain conforma-
tion of this residue are often related to larger-scale rearrange-
ments of the TMD. The MD simulations thus suggest that, in
addition to the rotation of the TMDs relative to each other
observed in the NMR structure of the constitutively active
VEGFR mutant, additional dynamic properties, such as sliding
of the helices, may be important for receptor activation.
A third conformation was observed in the V769E mutant TMD
andwas derived from the peptide trimer structure. There is, how-
ever, no evidence that such trimers are biologically relevant and
exist in the context of VEGFR-2 kinase constructs. V769E substi-
tution has clear biological consequences for activation of the
ECD-deleted VEGFR-2 construct, which is reflected neither in
an enhancement of the TMD dimerization propensity nor in
establishing a preferred dimeric conformation. Therefore, we
propose that the observed symmetric trimer structure describes
the pairwise helix-helix interactions present in constitutively
active, ECD-truncated V769E VEGFR-2 dimers. The symmetric
trimer structure may, however, give some insight into pairwise
helix-helix interactions. This conformation may allow for optimal
arrangement of the intracellular kinase domains but is–1089, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1085
Figure 9. Model of VEGF Receptor Activa-
tion
for details, see main text).
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VEGFR-2 Transmembrane Domain Structureincompatible with full-length constructs and does not promote
the long-lived asymmetric state of activating TMDs (Figure 5B;
Figure S8).
Because our structural analysis was performed with isolated
micelle-embedded peptidic TMDs, our conclusions may not be
unanimously applicable to the structure of full-length receptor
constructs. However, because the effect of the mutations on
the activity of VEGFR-2 agrees well with the observed structures
of TMD dimers, we are confident that our structural analysis is
also applicable to full-length receptors. In the absence of data
for full-length receptor constructs, our conclusions are consis-
tent and may provide relevant insights into the role of the TMD
in VEGFR-2 activation.
Taken together, we describe here a mechanism for VEGFR-2
activation that relies on two alternative TMD conformations, WT
and G770E/F777E. Comparing the structures of these TMDs
shows the reorientation of the mutant by rotating both helices
along the helical axis by 180. We propose the mechanism of re-
ceptor activation summarized in Figure 9 and Figure S8. In the
absence of ligand, the ECD maintains the receptor in an inactive
state, and receptor monomers exist in a dynamic monomer-
dimer equilibrium that is regulated by the intrinsic dimerization
propensity of the WT TMD. This preformed dimer may lower
the activation energy of the receptor. Ligand binding and subse-
quent formation of homotypic receptor ECD contacts leads to
the rotation of TMD helices by 180 relative to the inactive WT
conformation, presumably accompanied by sliding of the
TMDs relative to each other. Auto- and transphosphorylation
of tyrosine residues in the kinase and the carboxy-terminal re-
ceptor domain activates downstream signaling.
VEGF signaling is tightly controlled in vasculogenesis and
angiogenesis, as demonstrated by the embryonic lethality
observed upon VEGFR-2 ablation and heterozygous inactiva-
tion of VEGF-A (Shalaby et al., 1997; Shalaby et al., 1995; Fer-
rara et al., 1996). So far, disease-related, constitutively active
VEGFR-2 was only found in juvenile hemangiomas, resulting
from missense mutations in VEGFR-2, that lead to the downre-
gulation of the inhibitory soluble variant of VEGFR-1 (Jinnin
et al., 2008). Tight control of VEGFR-2 activity is therefore crit-
ical for vessel homeostasis and might be the consequence of
the inhibitory activity exerted by the receptor ECD (Brozzo
et al., 2012), which prevents aberrant dimerization in the
absence of ligand. We believe that future structural and func-
tional information on active, inactive, and transition-state
dimeric TMD conformations will open novel possibilities for1086 Structure 22, 1077–1089, August 5, 2014 ª2014 Elsevier Ltd All rights reservedthe design of compounds targeting the
hydrophobic milieu of the TMD.
EXPERIMENTAL PROCEDURES
Construction of Human VEGFR-2 TMD
Mutants
TMDmutants were cloned by introducing single or
double glutamic acid mutations into the WT TMD.As described before, all constructs were tagged with an amino-terminal hem-
agglutinin (HA) sequence as described (Dosch and Ballmer-Hofer, 2010). A
summary of all mutants is given in Figure S1.
Cell Culture and Kinase Activity Determination
HEK293 cell cultures were maintained and kinase activities were determined
as described (Dosch and Ballmer-Hofer, 2010) using the phospho-specific
antibody pY1175 (Cell Signaling Technology) and an antibody recognizing
the HA-tagged constructs (clone 3F10, Roche Diagnostics).
Cell-free Expression and Purification of VEGFR-2 TMD Peptides for
NMR Analysis
The nucleic acid sequences encoding the TMD peptides for the WT VEGFR-2-
tm peptide (MEKTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGG), the single
mutant VEGFR-2-tm769 (MEKTNLEIIILE769G TAVIAMFFWLLLVIILRTVKRA
NGG), and the double mutant VEGFR-2-tm770/777 (MEKTNLEIIILVE770
TAVIAME777FWLLLVIILR TVKRANGG) (all numbering according to P35968,
UniProt database, and the predicted TMD helix is underlined) were cloned
into the pET20b(+) vector (Novagen) at NdeI and HindIII. The resulting plas-
mids were named pET20b(+)/TMD-VEGFR-2 and pET20b(+)/TMD-VEGFR-
2(V769 to glutamic acid), respectively. All proteins were synthesized in the
continuous exchange cell-free expression system based on E. coli S30
extracts (Mineev et al., 2011; Bocharov et al., 2010).
NMR Spectroscopy and Calculation of Spatial Structures
NMR spectra were acquired at 45C on a 600-MHz Avance III spectrometer
(Bruker BioSpin) equipped with pulsed-field gradient, triple resonance cryo-
probes. The backbone and side chain 1H, 13C, and 15N resonances were
assigned using standard triple resonance techniques (Cavanagh, 2007) in
the CARA software (Keller, 2004). Triple resonance spectra were acquired
in a sparse sampling mode and processed with qMDD software (Orekhov
and Jaravine, 2011). NMR spatial structures of the VEGFR-2tm and
VEGFR-2tm770/777 homodimer and VEGFR-2tm769 homotrimer were
calculated using the CYANA program (Guentert, 2003). Assignment of the
experimental restraints and structure calculation was performed as described
previously (Bocharov et al., 2008; Bocharov et al., 2007).
Analysis of NMR Chemical Shifts
To investigate the spatial structure of the VEGFR-2tm769 dimer, we deter-
mined NMR chemical shifts. For this purpose, the shifts of NMR signals in
1H,15N-TROSY-HSQC occurring upon TMD dimerization were considered.
Shifts were characterized by vectors with coordinates Dd,UHDd,UH and
Dd,UNDd,UN, where DdDd and DdDd are changes in
1H and 15N chemical
shifts, whereasUHUH andUNUN are their Larmor frequencies. For two peptides
(VEGFR-2tm and VEGFR-2tm769), such vectors were calculated for each
residue, with the unambiguously determined assignment of dimeric andmono-
meric states, and the cosine of angle between these two vectors was plotted
versus the ratio of their modules to study the correlations in the N-H chemical
shift changes. Intermonomeric NOE contacts were identified directly from the
3D 15N,13C F1-filtered/F3-edited NOESY spectra (for details, see Supple-
mental Experimental Procedures).
Structure
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Energy of VEGFR-2 TMDs
To determine the oligomeric states of VEGFR-2tm, VEGFR-2tm 770/777, and
VEGFR-2tm769 and to measure the corresponding free energies of dimeriza-
tion and oligomerization, initial samples were diluted either with concentrated
DPC solution or distilled water to vary both the DPC concentration and the
protein/DPC ratio. At each point, a 1H,15N-TROSY-HSQC spectrum was
recorded. Populations of oligomeric states, aggregation numbers for the olig-
omeric states of VEGFR-2tm769, and the corresponding free energies of
dimerization/oligomerization equilibria were determined as described by
Mineev et al. (2014).Molecular Dynamics Simulations
The NMR structures of the WT and G770E/F777E mutant TMDs (residues
759–795) were used as initial coordinates for MD simulations. First, the proton-
ation state of titratable groups (except for glutamic acids, which were set as
neutral as measured by NMR) were calculated using PROPKA (Olsson et al.,
2000) at pH 7.0, as implemented in Protein Data Bank ID code 2PQR (Dolinsky
et al., 2004). The TMDswere then inserted in a hydrated lipid bilayer composed
of approximately 130 palmitoyl-oleoyl-phosphatidyl-choline molecules and
3,700 water molecules. Ions were added to a concentration of 0.15 M NaCl,
and additional ions were added to achieve charge neutrality. The system
measured roughly 503 503 80 A˚3, with a total of approximately 23,000 atoms.
This system was equilibrated as follows. First, a short (0.5-ns) simulation was
performed, in which only the lipid tails were allowed to move to induce the
appropriate disorder of a fluid-like bilayer. Next, the geometry of the entire
system was optimized by energy minimization, followed by equilibration steps
with the protein constrained (0.5 ns) and without constraints (0.5 ns). Simula-
tions were carried out using NAMD 2.8 (Phillips et al., 2005) with the
CHARMM27 all-hydrogen force field (MacKerell et al., 1998) at constant
temperature (300 K) and pressure (1 atmosphere) and using a time step of 2
femtosecond.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and two movies and can be found with this article online at
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